Adam Steensberg, CEO of Zealand Pharma, shares insights on his company’s innovative amylin-targeting obesity treatment and its strategic partnership with Roche, valued at $1.65 billion. He challenges industry norms by emphasizing sustainable weight loss over drastic changes. Robert Salcedo, CEO of OceanBio, discusses the unique biotech landscape in Puerto Rico, focusing on advancements in gene therapies and the potential for affordable medicine production. Together, they highlight the shifting priorities in obesity treatment and the resilient future of biotech in Puerto Rico.
